MEIP Key Stats
- Nasdaq stocks posting largest percentage decreases Dec 6
- MEI PHARMA, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Dec 6
- 4 Stocks Under $10 to Trade for Breakouts The Street Dec 6
- MEI Pharma To Host Analyst And Investor Day PR Newswire Dec 5
- Wedbush Starts MEI Pharma (MEIP) at Outperform Street Insider Dec 5
- MEI Pharma To Host Annual Meeting Of Stockholders PR Newswire Nov 26
- 4 Tech Stocks Under $10 Making Big Moves Nov 20
- MEI PHARMA, INC. Files SEC form 10-Q, Quarterly Report Nov 8
- MEI PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 29
- MEI Pharma (MEIP) Prices 4.38M Common Offering at $8/Share Street Insider Oct 25
MEIP Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). MEI Pharma is down 33.72% over the last year vs S&P 500 Total Return up 29.87%, Eisai down 7.78%, and Evoke Pharma up N/A.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for MEIP
Pro Strategies Featuring MEIP
Did MEI Pharma make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
MEI Pharma Inc is a development-stage oncology company engaged in the clinical development of novel small molecules for the treatment of cancer.